|  |
| --- |
| **Supplementary Table 1. Demographics and clinical characteristics for ASPIRE study and A5353 study.** |

| **Characteristics** | **ASPIRE (DTG+3TC) (n=18)** | **ASPIRE (3-drug) (n=20)** | **A5353 (DTG+3TC) (n=13)** |
| --- | --- | --- | --- |
| Age (years) |  |  |  |
| Median (IQR) | 43 (35-56) | 47 (41-52) | 29 (25-40) |
| HIV RNA level at baseline (copies/ml) |  |  |  |
| Median (IQR) | <20 | <20 | 29138 (13365-67968) |
| CD4+ at baseline (cells/µL) |  |  |  |
| Median (IQR) | 663 (528-812) | 710 (484-872) | 458 (336-671) |
| Time on ART at baseline (years) |  |  |  |
| Median (IQR)  Self-reported ART adherence\*, n (%) | 5.4 (3.5-7.6) | 6.2 (3.8-7.8) | ART naïve |
| No missed doses | 11 (61%) | 11 (55%) | 11 (85%) |
| Missed some doses | 7 (40%) | 9 (45%) | 2 (15%) |
| Sex, n (%) |  |  |  |
| Female | 3 (17%) | 2 (10%) | 1 (8%) |
| Male | 15 (83%) | 18 (90%) | 12 (92%) |

**Legend:** IQR: Interquartile Range, ART: antiretroviral therapy, n: number, \* Self-reported ART Adherence during study follow-up

**Supplementary Figure 1. HIV RNA in genital secretion among ASPIRE and A5353 participants**

Levels of HIV RNA in genital secretion among A5353 antiretroviral-naïve participants who initiated DTG+3TC and virologically suppressed ASPIRE participants (divided by study arm, i.e. three-drug ART or switch to DTG+3TC). Lower limit of detection of the genital HIV RNA assay is 40 copies/ml.

